A Randomized Phase II Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab in Patients with Advanced Gastrointestinal Stromal Tumors.
Arun S SinghJ Randolph HechtLee RosenZev A WainbergXiaoyan WangMichael DouekAnahis HagopianRachel AndesLauren SauerSandra R BrackertWarren ChowRonald DeMatteoFritz Christian EilberJohn A GlaspyBartosz ChmielowskiPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
The primary endpoint of response rate > 15% was not observed for N or N + I. In a heavily pretreated GIST population, responses and long-term disease control with both N and N+I were observed. No new safety signals have been observed.